ADARx Pharmaceuticals, Inc. (ADRX) income statement
ADRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Last filing: 10-Q on Nov 12, 2026
$14.16+1.34 (+10.45%)
Close on Nov 19, 2026Market cap $1.52BP/E –Yield –
ADARx Pharmaceuticals, Inc. income statement
AnnualQuarterlyTTM
This company has not reported income statement data in its XBRL filings.
Ratios
Latest available
Profitability, FY
- Gross margin
- –
- Operating margin
- –
- Net margin
- –
- Return on equity, FY
- –
Financial strength
- Current ratio
- –
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- –
Valuation
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 2.64
- Dividend yield
- –
See a number that looks wrong?